ATLANTA — Stephen M. Hahn, MD, chairman of the Department of Radiation Oncology and Henry K. Pancost Professor of Radiation Oncology in the Perelman School of Medicine and Abramson Cancer Center at the University of Pennsylvania, has been named among the ten 2013 Fellows of the American Society for Radiation Oncology.
Dr. Hahn became the chair of Penn Medicine’s Department of Radiation Oncology in 2005, after joining Penn’s faculty in 1996. During his tenure, he has overseen the opening of the Roberts Proton Therapy Center, the world’s largest and most advanced center integrating both proton beam radiation therapy and conventional radiation.
He received the FASTRO recognition this week during the organization’s 55th Annual Meeting at the Georgia World Congress Center in Atlanta.
Awarded annually since 2006, ASTRO’s Fellows Program honors radiation oncology leaders who have been an ASTRO member for at least 15 years and have made substantial contributions to the field of radiation oncology in the areas of research, education, patient care or service, and leadership. Including the 2013 class of 10 Fellows, 212 of ASTRO’s more than 10,000 members worldwide have received the FASTRO designation.
Prior to his arrival at Penn, Dr. Hahn served as chief of the National Cancer Institute’s Prostate Cancer Clinic, Clinical Pharmacology Branch, in Bethesda, MD, and as senior investigator at the NCI. He also served as a Commander in the NCI’s U.S. Public Health Service from 1989 to 1995.
Dr. Hahn’s research and clinical care concentrates on cancers of the lung and genitourinary system, as well as radiation biology and photodynamic therapy. He is board certified in Internal Medicine, Radiation Oncology, and Hematology/Oncology, and is a graduate of the Temple University School of Medicine and Rice University. He completed his internal medicine residency at the University of California, San Francisco and received fellowship training in both medical oncology and radiation oncology at the NCI. He has been a longtime member and leader of various ASTRO committees and initiatives.
“These 10 new Fellows join an elite group of ASTRO members who have significantly impacted ASTRO, the specialty and cancer patients worldwide through their leadership in and service to research, education and patient care efforts,” said ASTRO President Colleen A. F. Lawton, MD, FASTRO. “Congratulations to my esteemed colleagues on receiving the ASTRO Fellow designation.”
To read more about the 2013 FASTRO awardees, visit the ASTRO web site.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.